Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Finn

Showing results (51-60 of 407) with videos related to

Pageof 41
Sort By:
Current Opinion in Immunology|March 1, 2002
Prophylactic cancer vaccinesOlivera J Finn, Guido Forni
Biomolecules|October 19, 2016
Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and MetastasisSandra Cascio, Olivera J Finn
Pharmacology & Therapeutics|March 22, 2017
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccinesJason Lohmueller, Olivera J Finn
Expert Opinion on Biological Therapy|September 25, 2012
MUC1 immunotherapy is here to stayTakashi Kimura, Olivera J Finn
Journal of Bacteriology|August 1, 1975
Regulation of catalase synthesis in Salmonella typhimuriumG J Finn, S Condon
Current Pharmaceutical Design|January 30, 2010
Cancer vaccines: emphasis on pediatric cancersTerri Guinipero, Olivera J Finn
The Journal of Experimental Medicine|October 30, 2009
INSULIN ANTIBODY VARIATIONS IN RABBITS AND GUINEA PIGS AND MULTIPLE ANTIGENIC DETERMINANTS ON INSULINE R Arquilla, J Finn
Seminars in Immunology|April 11, 2020
Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunopreventionCamille Jacqueline, Olivera J Finn
Cancer Immunology, Immunotherapy : CII|July 21, 2005
DNA vaccines for cancer tooMin Yu, Olivera J Finn
Cancer Research|June 19, 2001
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patientsJ Schmielau, O J Finn
Pageof 41

Showing results (51-60 of 407) with videos related to

Sort By:
Pageof 41
Current Opinion in Immunology|March 1, 2002
Prophylactic cancer vaccinesOlivera J Finn, Guido Forni
Biomolecules|October 19, 2016
Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and MetastasisSandra Cascio, Olivera J Finn
Pharmacology & Therapeutics|March 22, 2017
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccinesJason Lohmueller, Olivera J Finn
Expert Opinion on Biological Therapy|September 25, 2012
MUC1 immunotherapy is here to stayTakashi Kimura, Olivera J Finn
Journal of Bacteriology|August 1, 1975
Regulation of catalase synthesis in Salmonella typhimuriumG J Finn, S Condon
Current Pharmaceutical Design|January 30, 2010
Cancer vaccines: emphasis on pediatric cancersTerri Guinipero, Olivera J Finn
The Journal of Experimental Medicine|October 30, 2009
INSULIN ANTIBODY VARIATIONS IN RABBITS AND GUINEA PIGS AND MULTIPLE ANTIGENIC DETERMINANTS ON INSULINE R Arquilla, J Finn
Seminars in Immunology|April 11, 2020
Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunopreventionCamille Jacqueline, Olivera J Finn
Cancer Immunology, Immunotherapy : CII|July 21, 2005
DNA vaccines for cancer tooMin Yu, Olivera J Finn
Cancer Research|June 19, 2001
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patientsJ Schmielau, O J Finn
Pageof 41